EGFR
EGFR is a master receptor tyrosine kinase that serves as the "antenna" for cellular growth signals. By sensing epidermal growth factors and triggering downstream cascades like MAPK and PI3K, it coordinates tissue repair and regeneration; however, activating mutations in its kinase domain are foundational drivers of aggressive lung and brain cancers, defining the era of precision oncology.
Key Takeaways
- •EGFR is a primary "growth antenna" on the cell surface that senses external signals to initiate division.
- •In many lung cancers, mutations in EGFR lock the antenna in the "on" state, driving tumor growth.
- •EGFR is essential for the health of the skin and gut; inhibitors of this gene frequently cause a characteristic skin rash.
- •The history of EGFR treatments—from Erlotinib to Osimertinib—represents the gold standard of precision cancer medicine.
- •Aging-related decline in EGFR activity in stem cell niches is a major cause of thinning skin and delayed wound healing.
Basic Information
- Gene Symbol
- EGFR
- Full Name
- Epidermal Growth Factor Receptor
- Also Known As
- HER1ERBBERBB1PIG61
- Location
- 7p11.2
- Protein Type
- Receptor Tyrosine Kinase
- Protein Family
- ERBB family
Related Isoforms
The canonical full-length receptor involved in growth factor signaling.
A common oncogenic variant lacking the extracellular ligand-binding domain.
Key SNPs
Associated with altered response to EGFR inhibitors in colorectal cancer patients.
Affects promoter activity and expression levels; linked to variations in lung cancer risk.
Located in a let-7 miRNA binding site; associated with survival in several epithelial cancers.
Major activating mutation in NSCLC; target for first-generation tyrosine kinase inhibitors.
The "gatekeeper" mutation that confers resistance to early-generation EGFR inhibitors.
The most common activating deletion in lung adenocarcinoma; highly sensitive to TKIs.
Overview
EGFR (Epidermal Growth Factor Receptor), also known as HER1 or ERBB1, is a master regulator of epithelial tissue growth and repair. It is a receptor tyrosine kinase—a protein that sits in the cell membrane, sensing signals from the environment and translating them into chemical actions inside the cell. When a growth factor (like EGF) binds to the receptors external part, two receptors pair up ("dimerize") and activate their internal kinase domains, sparking a chain reaction of survival and division signals.
In a healthy organism, EGFR is the architect of the skin and intestinal lining, ensuring these rapidly-turning-over tissues are constantly replenished. However, because it is so powerful, EGFR is frequently hijacked by cancer cells. Activating mutations or gene amplification can leave the receptor permanently active, sending a relentless "grow" signal that results in some of the most aggressive forms of human cancer.
Conceptual Model
A simplified mental model for the pathway:
Activating mutations bypass the ligand requirement, leaving the growth spark permanently on.
Core Health Impacts
- • Epithelial Repair: Essential for the maintenance and rapid repair of skin and gut linings.
- • Oncogenesis Driver: Major driver of tumorigenesis when hyperactivated by mutation or amplification.
- • Inflammation: Mediates inflammatory responses in the lungs and skin upon ligand binding.
- • Neural Plasticity: Plays a role in early neural development and the maintenance of synaptic plasticity.
- • Wound Closure: Directly regulates the speed and efficiency of cell migration during wound healing.
Protein Domains
Extracellular
Four subdomains that facilitate ligand binding and receptor dimerization.
Kinase Domain
Intracellular region that catalyzes the transfer of phosphate from ATP to tyrosine.
C-Terminal Tail
Rich in docking sites for downstream signaling adaptors like Grb2.
Upstream Regulators
Epidermal Growth Factor (EGF) Activator
The primary ligand; binds the extracellular domain to induce dimerization.
TGF-alpha Activator
Potent mitogen that signals through EGFR to promote rapid cell proliferation.
Amphiregulin (AREG) Activator
Ligand involved in tissue repair and development; often upregulated in tumors.
HB-EGF Activator
Heparin-binding ligand; contributes to wound healing and cardiac development.
Betacellulin (BTC) Activator
Pan-ERBB ligand that can activate multiple members of the EGFR family.
Epiregulin (EREG) Activator
Low-affinity ligand associated with prolonged signaling and tumor progression.
Downstream Targets
MAPK / ERK Pathway Activates
Drives cell proliferation and differentiation downstream of RAS/RAF.
PI3K / AKT Pathway Activates
Regulates cell growth and apoptosis resistance; critical for metabolism.
STAT 3/5 Activates
Transcription factors that mediate survival signals and immune modulation.
PLC-gamma / PKC Activates
Regulates intracellular calcium and protein kinase C, influencing cell migration.
Src Kinase Activates
Interacts with EGFR to amplify signals and promote invasive behavior in tumor cells.
Grb2 / SOS Activates
Adaptor proteins that recruit RAS to the membrane to initiate the MAPK cascade.
Role in Aging
EGFR signaling is central to the regenerative capacity of aging tissues. Its balance determines whether an organ can successfully repair itself or if it succumbs to age-related thinning and cancer.
Tissue Thinning
Declining EGFR activity in stem cell niches leads to the thinning of skin and gut epithelia in the elderly.
Delayed Healing
Age-related reduction in receptor sensitivity slows down the migration of cells needed for wound closure.
SASP Production
Persistent RTK signaling can fuel the Senescence-Associated Secretory Phenotype, driving inflammaging.
Autophagy Block
Chronic EGFR activation of the mTOR axis can suppress the cleanup of damaged organelles over time.
Metabolic Decay
EGFR intersects with insulin signaling; its dysregulation can contribute to age-related metabolic shifts.
Tumor Susceptibility
The accumulation of activating EGFR mutations in healthy tissues is a major risk factor for late-life cancer.
Disorders & Diseases
Lung Adenocarcinoma (NSCLC)
Activating mutations like L858R define a specific subset of lung cancers that are "addicted" to EGFR signaling.
Glioblastoma Multiforme
The most aggressive brain cancer often features EGFR amplification or the EGFRvIII truncated variant.
Colorectal Cancer
Overexpression of wild-type EGFR is common; treatment requires checking for downstream KRAS mutations.
Pancreatic Cancer
Upregulation of EGFR and its ligands contributes to the aggressive nature and fibrotic environment of PDAC.
Polycystic Kidney Disease
Hyperactive EGFR signaling drives the excessive proliferation of tubular cells that form renal cysts.
Interventions
Supplements
Reported to downregulate EGFR expression and inhibit downstream signaling in research models.
Catechin that can interfere with EGFR tyrosine kinase activity and reduce growth signaling.
Soy isoflavone studied for its potential to inhibit receptor tyrosine kinases like EGFR.
Flavonoid that may modulate growth factor pathways through its antioxidant and kinase-inhibitory effects.
May influence the lipid raft environment where EGFR is localized, potentially damping signaling.
Lifestyle
The primary way to prevent the chemical modifications that lead to EGFR-mutant lung cancers.
Particulate matter exposure can trigger chronic lung inflammation and RTK activation.
Reducing insulin and IGF-1 tone lowers the auxiliary pressure on EGFR growth pathways.
UV damage can synergize with EGFR pathways to promote skin damage and carcinogenesis.
Medicines
Third-generation irreversible inhibitor that targets the T790M resistance mutation.
First-generation inhibitors that target activating mutations in the EGFR kinase domain.
Monoclonal antibody that blocks the extracellular ligand-binding site of the receptor.
Second-generation pan-ERBB inhibitor that irreversibly blocks EGFR, HER2, and HER4.
Dual inhibitor of both EGFR and HER2 used primarily in breast cancer therapy.
Lab Tests & Biomarkers
Genetic Testing
Next-Generation Sequencing to identify sensitizing and resistance EGFR mutations.
Non-invasive blood test to detect and monitor EGFR mutations during treatment.
Pathology
Standard stain to assess the density of EGFR protein on the surface of tumor cells.
Tests for gene amplification or increased copy number at the 7p11 locus.
Pathway Readouts
Research marker for the active, phosphorylated state of the receptor.
Hormonal Interactions
Estrogen Crosstalk Partner
Estrogen receptors can bidirectionally interact with EGFR to drive growth in breast and lung tissue.
Insulin Indirect Amplifier
Elevated insulin can increase the bioavailability of ligands that activate EGFR pathways.
IGF-1 Synergistic Partner
Often shares signaling nodes with EGFR; the two receptors can heterodimerize.
Cortisol Feedback Modulator
Glucocorticoids can influence the expression of EGFR and its ligands during chronic stress.
Deep Dive
Network Diagrams
The EGFR Activation Cycle
Evolution of TKI Resistance
Activation Mechanics: The Dimerization Arm
Unlike many other receptors, EGFR does not rely solely on the growth factor to pull two pieces together. Instead, ligand binding induces a massive shape change that exposes a “dimerization arm.”
- The Handshake: This arm reaches out and interacts with a partner receptor. In this active pair, one receptor acts as the “activator” and physically pushes against its partner (the “receiver”), inducing an active shape in its kinase domain.
- Asymmetric Switch: This unique asymmetric activation is the defining feature of the ERBB family. It allows EGFR to heterodimerize with other members like HER2, which is often more stable and produces more potent signals than an EGFR-only pair.
Resistance Evolution: The TKI Battle
The history of EGFR in lung cancer is a classic study in the evolutionary battle between drugs and cancer.
- The Gatekeeper (T790M): When patients were treated with first-generation drugs like Erlotinib, their tumors initially shrank. However, the cancer often “escaped” by developing the T790M mutation. This change increases the receptors affinity for ATP, physically pushing the drug out of the kinase pocket.
- The Covalent Solution: Third-generation drugs like Osimertinib were designed specifically to overcome this. They form a permanent, covalent bond with the receptor, ensuring the switch stays off even in the presence of the resistance mutation.
Bypass Pathways: Signaling Around the Block
If the cell cannot break the lock on EGFR, it often finds a way to build a “bypass road.”
Instead of mutating the receptor further, some tumors upregulate other receptors like MET or AXL. These alternative antennas use the same internal wiring (MAPK and PI3K) as EGFR. Even if the EGFR “front door” is locked by a drug, the cell continues to receive growth signals through these “side doors,” highlighting why combination therapies are often necessary for long-term control.
Interpreting EGFR Status
Sensitizing vs Resistance. In lung cancer, finding an Exon 19 del or L858R means the tumor is highly likely to respond to TKIs.
Wild-type Overexpression. High levels of normal EGFR usually suggest benefit from antibody therapies, provided downstream genes like KRAS are not mutated.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Pivotal discovery identifying EGFR mutations as the predictor of treatment success in lung cancer.
Established third-generation TKIs as the standard of care for overcoming common resistance.
Foundational review establishing the logic for targeting the EGFR family in clinical oncology.
Detailed study of how receptor trafficking shapes the intensity and duration of the signal.